Quintiles has introduced Allume, a go-to-market service designed to help biopharmaceutical companies efficiently launch new products and shorten timelines to sales. According to the company, Allume simplifies and organizes the complex and resource-intensive launch planning process, provides data-driven insights from 15 years of market entry experience across the globe, and leverages Quintiles’ local market and therapeutic category expertise.
Allume incorporates Quintiles’ biopharma product launch experience and can be customized to each company and product to help identify key market challenges, fast-track launches and improve efficiency in resource management.
“Allume coordinates decision making around the late phases of development as well as the launch of an asset,” said Dr. Michael Ackermann, senior vice president, Global Commercial Solutions at Quintiles. “It is a well-structured and interactive way of accessing the expertise customers need without surrendering strategic control of their asset.”